ISOXILAN Isoxsuprine Hydrochloride 5mg / mL Solution for IM/IV Injection 2mL 1's
RXDRUG-DR-XY28201
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Isoxilan
Full Details
Dosage Strength
5 mg / mL
Drug Ingredients
- Isoxsuprine
Drug Packaging
Solution for Injection (I.M./I.V.) 2ml x 1's
Generic Name
Isoxsuprine Hcl
Dosage Form
Solution For Injection (I.M./I.V.)
Registration Number
DR-XY28201
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Uterine hypermotility disorders such as threatened abortion and uncomplicated premature labor.
An adjunct therapy in the treatment of peripheral vascular disease such as arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease), and Raynaud's disease.
For the relief of symptoms associated with cerebrovascular insufficiency.
An adjunct therapy in the treatment of peripheral vascular disease such as arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease), and Raynaud's disease.
For the relief of symptoms associated with cerebrovascular insufficiency.
Dosage/Direction for Use
Uterine Hypermotility: See Table 1.
Maintain patients in preterm labor in the lateral position during infusion.
Monitor blood pressure (maternal) and heart rate (maternal and fetal) regularly during infusion and reduce the rate of infusion or discontinue infusion if prolonged fall in blood pressure occurs.
Circulatory Disturbances: See Table 2.
Maintain patients in preterm labor in the lateral position during infusion.
Monitor blood pressure (maternal) and heart rate (maternal and fetal) regularly during infusion and reduce the rate of infusion or discontinue infusion if prolonged fall in blood pressure occurs.
Circulatory Disturbances: See Table 2.
IM administration may be used for the initial control of acute severe symptoms, after which patients are maintained on oral therapy.
Overdosage
Overdosage with isoxsuprine has not been reported. When this occurs, however, cardiovascular symptoms are expected.
Overdosage with the oral format should be managed by gastric lavage. A nonselective β-blocker may be administered intramuscularly if necessary.
Overdosage with the oral format should be managed by gastric lavage. A nonselective β-blocker may be administered intramuscularly if necessary.
Administration
May be taken with or without food: May be taken w/ meals, milk or antacids to minimise GI discomfort.
Contraindications
Following recent arterial hemorrhage; In patients with known heart disease; In patients with severe anemia.
Parenteral use of isoxsuprine hydrochloride is also contraindicated in the following conditions: Hypotension; Tachycardia; Premature detachment of the placenta; Immediately postpartum; Premature labor if there is infection.
Parenteral use of isoxsuprine hydrochloride is also contraindicated in the following conditions: Hypotension; Tachycardia; Premature detachment of the placenta; Immediately postpartum; Premature labor if there is infection.
Special Precautions
Immediately discontinue isoxsuprine treatment if rash develops.
To avoid pulmonary edema in women being treated for premature labor, very carefully monitor the patient's state of hydration, and cardiac and respiratory function. Keep fluid infusion volume to the minimum. For infusion, hypotonic dextrose is preferred over isotonic saline solution. Discontinue isoxsuprine immediately and institute diuretic therapy when signs of pulmonary edema develop.
Use in Children: lsoxsuprine is not indicated for pediatric patients.
Use in Elderly: No specific information is available on the use of isoxsuprine in elderly patients. lsoxsuprine may reduce tolerance to cold temperatures in these patients.
To avoid pulmonary edema in women being treated for premature labor, very carefully monitor the patient's state of hydration, and cardiac and respiratory function. Keep fluid infusion volume to the minimum. For infusion, hypotonic dextrose is preferred over isotonic saline solution. Discontinue isoxsuprine immediately and institute diuretic therapy when signs of pulmonary edema develop.
Use in Children: lsoxsuprine is not indicated for pediatric patients.
Use in Elderly: No specific information is available on the use of isoxsuprine in elderly patients. lsoxsuprine may reduce tolerance to cold temperatures in these patients.
Use In Pregnancy & Lactation
Ileus and respiratory distress syndrome has been found to be more common in the offspring of pregnant women who received isoxsuprine. Incidence of respiratory distress syndrome increases as the isoxsuprine concentration in cord blood exceeds 10 ng/mL. The incidence of hypocalcemia and hypotension rises progressively with increasing isoxsuprine concentration in the cord blood.
Use isoxsuprine in pregnant women only when the potential benefit outweighs the potential risk to mother and infant.
There are no reports of problems with isoxsuprine in breastfeeding babies.
Use isoxsuprine in pregnant women only when the potential benefit outweighs the potential risk to mother and infant.
There are no reports of problems with isoxsuprine in breastfeeding babies.
Adverse Reactions
Isoxsuprine adverse effects may include trembling, nervousness, weakness, dizziness, flushing, transient palpitation, tachycardia, chest pain, hypotension, abdominal distress, nausea, vomiting, intestinal distention, and severe rash.
Parenteral isoxsuprine administration can result in tachycardia, palpitations, hypotension, dizziness, and flushing. These can be controlled by dose reduction and by supine position of the patient. These effects are reversed, if necessary, by parenteral administration of noradrenaline.
Isoxsuprine may also cause slight increase in fetal heart rate if used as IV infusion in premature labor.
Parenteral isoxsuprine administration can result in tachycardia, palpitations, hypotension, dizziness, and flushing. These can be controlled by dose reduction and by supine position of the patient. These effects are reversed, if necessary, by parenteral administration of noradrenaline.
Isoxsuprine may also cause slight increase in fetal heart rate if used as IV infusion in premature labor.
Drug Interactions
Isoxsuprine may cause severe hypotension when administered with other vasodilators and anti-hypertensive drugs.
Storage
Store at temperatures not exceeding 30°C. Protect from light.
Action
Pharmacology: Pharmacodynamics: Isoxsuprine hydrochloride is a β2-adrenoceptor agonist that causes vasodilation by direct relaxation of vascular smooth muscle. Its β2-adrenergic effects, however, are not essential to its vasodilating effect. Isoxsuprine decreases peripheral vascular resistance; blood pressure may be decreased by parenteral administration or large oral doses of isoxsuprine. lsoxsuprine may also have positive inotropic and chronotropic effects on the heart and may increase cardiac output.
Isoxsuprine also relaxes uterine smooth muscle and is valuable in arresting contractions in threatened abortion and premature labor.
Pharmacokinetics: Isoxsuprine is almost completely absorbed from the gastrointestinal tract after oral administration and peak plasma concentrations occur within 1 hour and persist for about 3 hours. lsoxsuprine's mean plasma half-life is about 1.25 hours. It crosses the placenta.
Isoxsuprine is conjugated partially in the body and is excreted in urine. Isoxsuprine's fecal excretion is negligible.
No data is available on the onset of effect and peak plasma concentration of isoxsuprine hydrochloride when administered parenterally. With intramuscular (IM) injection, isoxsuprine's effect lasts for 3 to 4 hours.
Isoxsuprine also relaxes uterine smooth muscle and is valuable in arresting contractions in threatened abortion and premature labor.
Pharmacokinetics: Isoxsuprine is almost completely absorbed from the gastrointestinal tract after oral administration and peak plasma concentrations occur within 1 hour and persist for about 3 hours. lsoxsuprine's mean plasma half-life is about 1.25 hours. It crosses the placenta.
Isoxsuprine is conjugated partially in the body and is excreted in urine. Isoxsuprine's fecal excretion is negligible.
No data is available on the onset of effect and peak plasma concentration of isoxsuprine hydrochloride when administered parenterally. With intramuscular (IM) injection, isoxsuprine's effect lasts for 3 to 4 hours.
MedsGo Class
Drugs Acting on the Uterus / Peripheral Vasodilators & Cerebral Activators
Please sign in so that we can notify you about a reply